Third-year medical student in the Department of Dermatology, University of Missouri-Columbia School of Medicine.
Philip C. Anderson Chair and Professor Departments of Dermatology and Child Health, also at University of Missouri-Columbia, Columbia, Missouri.
Mo Med. 2023 Jan-Feb;120(1):45-48.
A number of chronic skin diseases, such as vitiligo and alopecia areata, are historically resistant to or respond poorly to treatment. Additionally, disorders such as atopic dermatitis and psoriasis have subtypes that are inadequately treated by current medications. Lastly, in the field of dermatology there are a number of conditions, some genetic (such as Darier's disease and Hailey-Hailey disease) and others caused by aberrant inflammatory responses (macrophage-driven conditions such as sarcoidosis and autoimmune conditions such as localized scleroderma) where effective treatments have been limited to date. A new class of anti-inflammatory medications that inhibit the Janus Kinase-Signal transducer and activator of transcription pathway (JAK-STAT) show great promise in providing new and effective treatment of these formerly recalcitrant conditions. This brief review will cover inhibitors of the JAK-STAT pathway (JAK inhibitors) currently approved for use in treating dermatologic diseases including several very recently approved medications. It will also touch on additional conditions under study or where early reports of efficacy are promising.
许多慢性皮肤病，如白癜风和斑秃，在历史上对治疗有抵抗力或反应不佳。此外，特应性皮炎和银屑病等疾病有一些亚型，目前的药物治疗效果不佳。最后，在皮肤科领域，有许多疾病，有些是遗传的（如 Darier 病和 Hailey-Hailey 病），有些是由异常炎症反应引起的（如巨噬细胞驱动的疾病，如结节病，自身免疫性疾病，如局限性硬皮病），迄今为止，有效的治疗方法一直很有限。一类新的抗炎药物，即抑制 Janus 激酶-信号转导和转录激活因子（JAK-STAT）通路的药物，在为这些以前难以治疗的疾病提供新的有效治疗方法方面显示出巨大的前景。这篇简要综述将涵盖目前批准用于治疗皮肤科疾病的 JAK-STAT 通路抑制剂（JAK 抑制剂），包括最近批准的几种药物。它还将涉及正在研究的其他疾病，或早期疗效报告有希望的疾病。
